

Beining Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8045894/publications.pdf>

Version: 2024-02-01

32
papers

283
citations

1039406

9
h-index

996533

15
g-index

34
all docs

34
docs citations

34
times ranked

230
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of ultra-performance liquid chromatography-tandem mass spectrometric methods for simultaneous and rapid determination of contezolid and its major metabolite M2 in plasma and urine samples and its application to a study in subjects with moderate liver impairment. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022, 1191, 123129.	1.2	5
2	Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaOXA-23-harboring CRAB in In Vitro PK/PD Model. <i>Molecules</i> , 2022, 27, 1085.	1.7	4
3	Case Report: Therapeutic Drug Monitoring of Polymyxin B During Continuous Renal Replacement Therapy in Two Pediatric Patients: Do Not Underestimate Extracorporeal Clearance. <i>Frontiers in Pharmacology</i> , 2022, 13, 822981.	1.6	0
4	Proteomic Response Revealed Signaling Pathways Involving in the Mechanism of Polymyxin B-Induced Melanogenesis. <i>Microbiology Spectrum</i> , 2022, 10, e0273021.	1.2	1
5	Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0243021.	1.4	5
6	Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against <i>Acinetobacter baumannii</i> in Patients with Hospital-Acquired Pneumonia. <i>Antibiotics</i> , 2022, 11, 703.	1.5	4
7	Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects. <i>Journal of Infection</i> , 2021, 82, 207-215.	1.7	24
8	Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis. <i>Infectious Diseases and Therapy</i> , 2021, 10, 911-923.	1.8	1
9	Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against <i>Streptococcus Pneumoniae</i> . <i>Frontiers in Pharmacology</i> , 2021, 12, 658558.	1.6	4
10	Nemonoxacin dosage adjustment in patients with severe renal impairment based on population pharmacokinetic and pharmacodynamic analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4636-4647.	1.1	3
11	Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0040921.	1.4	9
12	Degradation of vancomycin in external quality assessment samples is a factor to underestimate its concentration. <i>Bioanalysis</i> , 2021, 13, 1743-1750.	0.6	0
13	Nemonoxacin Has Immunoprotective Effects on Reducing Mortality in Lipopolysaccharide-Induced Mouse Sepsis Model. <i>Inflammation</i> , 2020, 43, 2276-2286.	1.7	0
14	Simultaneous separation and determination of vancomycin and its crystalline degradation products in human serum by ultra high performance liquid chromatography tandem mass spectrometry method and its application in therapeutic drug monitoring. <i>Journal of Separation Science</i> , 2020, 43, 3987-3994.	1.3	10
15	Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients. <i>Clinical Therapeutics</i> , 2020, 42, 818-829.	1.1	13
16	Therapeutic drug monitoring of polymyxin B by LC-MS/MS in plasma and urine. <i>Bioanalysis</i> , 2020, 12, 845-855.	0.6	11
17	Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	11
18	An ultra-performance liquid chromatography-tandem mass spectrometry method to quantify vancomycin in human serum by minimizing the degradation product and matrix interference. <i>Bioanalysis</i> , 2019, 11, 941-955.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis. <i>Clinical Therapeutics</i> , 2019, 41, 1164-1174.e4.	1.1	18
20	Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment. <i>Clinical Therapeutics</i> , 2019, 41, 505-517.e0.	1.1	4
21	Determination of DPâ€VPA and its active metabolite, VPA, in human plasma, urine, and feces by UPLCâ€MS/MS: A clinical pharmacokinetics and excretion study. <i>Drug Testing and Analysis</i> , 2019, 11, 1035-1047.	1.6	7
22	Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatographyâ€tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1081-1082, 87-100.	1.2	7
23	Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects. <i>Clinical Therapeutics</i> , 2018, 40, 322-332.e5.	1.1	23
24	Pharmacokinetics and Pharmacodynamics of Levornidazole in Patients With Intra-abdominal Anaerobic Infection. <i>Clinical Therapeutics</i> , 2018, 40, 1548-1555.	1.1	4
25	Clinical Pharmacokinetics of Levornidazole in Elderly Subjects and Dosing Regimen Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis. <i>Clinical Therapeutics</i> , 2017, 39, 1336-1346.	1.1	3
26	Improved pharmacokinetic profile of levornidazole following intravenous infusion of 750mg every 24h compared with 500mg every 12h in healthy Chinese volunteers. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 224-228.	1.1	7
27	Determination of a novel nonfluorinated quinolone, nemonoxacin, in human feces and its glucuronide conjugate in human urine and feces by highâ€performance liquid chromatographyâ€triple quadrupole mass spectrometry. <i>Biomedical Chromatography</i> , 2015, 29, 739-748.	0.8	2
28	Development of an Liquid Chromatographyâ€Tandem Mass Spectrometry Method for the Determination of Amoxicillin in Broth Medium and its Application to an In Vitro Pharmacokinetic and Pharmacodynamic Model. <i>Journal of Chromatographic Science</i> , 2015, 54, bmv139.	0.7	4
29	Quantification of levornidazole and its metabolites in human plasma and urine by ultra-performance liquid chromatographyâ€mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 963, 119-127.	1.2	8
30	Safety and Clinical Pharmacokinetics of Nemonoxacin, a Novel Non-Fluorinated Quinolone, in Healthy Chinese Volunteers Following Single and Multiple Oral Doses. <i>Clinical Drug Investigation</i> , 2012, 32, 475-486.	1.1	38
31	A liquid chromatographyâ€tandem mass spectrometry assay for the determination of nemonoxacin (TCâ€873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a singleâ€dose pharmacokinetic study in healthy Chinese volunteers. <i>Biomedical Chromatography</i> , 2012, 26, 1333-1340.	0.8	11
32	Pathogenic Implication of a Fibrinogen-Binding Protein of <i>Staphylococcus epidermidis</i> in a Rat Model of Intravascular-Catheter-Associated Infection. <i>Infection and Immunity</i> , 2007, 75, 2991-2995.	1.0	31